Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07. Submission of Matters to a Vote of Security Holders
Novelion Therapeutics Inc. (the Company) held its 2017 annual
general meeting of shareholders (the Annual Meeting) on June28,
2017. The shareholders of the Company considered and acted upon
the following proposals:
Election of Directors.
The Companys shareholders elected Jason M. Aryeh, Mark Corrigan,
Geoffrey Cox, Kevin Kotler, Jorge Plutzky, Stephen Sabba, Donald
Stern, Mary Szela and John Thomas,Jr. to serve on the Board of
Directors of the Company (the Board) until the Companys 2018
Annual General Meeting of shareholders, and until their
successors are duly elected and qualified. The voting results for
this proposal were as follows:
|
Nominee |
|
For |
|
Against |
|
Abstentions |
|
BrokerNon-Votes |
|
|
Jason M. Aryeh |
10,380,782 |
|
22,764 |
2,557,771 |
|||||
|
Mark Corrigan |
10,385,027 |
|
18,519 |
2,557,771 |
|||||
|
Geoffrey Cox |
9,640,543 |
|
763,003 |
2,557,771 |
|||||
|
Kevin Kotler |
10,384,245 |
|
19,301 |
2,557,771 |
|||||
|
Jorge Plutzky |
10,385,347 |
|
18,199 |
2,557,771 |
|||||
|
Stephen Sabba |
10,377,878 |
|
25,668 |
2,557,771 |
|||||
|
Donald Stern |
10,379,229 |
|
24,317 |
2,557,771 |
|||||
|
Mary Szela |
10,384,415 |
|
19,131 |
2,557,771 |
|||||
|
John Thomas,Jr. |
9,640,867 |
|
762,679 |
2,557,771 |
Appointment of Auditors.
The Companys shareholders voted to appoint Deloitte Touche LLP as
the Companys independent registered public accounting firm for
the fiscal year ended December31, 2017. The voting results for
this proposal were as follows:
|
For |
|
Against |
|
Abstaining |
|
BrokerNon-Votes |
|
12,940,006 |
|
21,311 |
|
Advisory Vote to Approve the Compensation of Named
Executive Officers.
The Companys shareholders approved, on an advisory, non-binding
basis, the compensation paid to the named executive officers of
the Company, as disclosed in the Companys definitive proxy
statement on Schedule 14A relating to the Annual Meeting, as
filed with the Securities Exchange Commission (the Commission) on
May1, 2017 (the Proxy Statement). The voting results for this
proposal were as follows:
|
For |
|
Against |
|
Abstaining |
|
BrokerNon-Votes |
|
10,337,640 |
65,906 |
|
2,557,771 |
Advisory Vote on the Frequency of the Advisory Vote
to Approve the Compensation of Named Executive
Officers.
The Companys shareholders approved, on an advisory, non-binding
basis, that the frequency of future advisory votes to approve the
compensation paid to the named executive officers of the Company
be conducted annually. The voting results for this proposal were
as follows:
|
For |
|
Against |
|
Abstaining |
|
BrokerNon-Votes |
|
10,127,332 |
276,214 |
|
2,557,771 |
Consistent with Boards recommendation and the results of the
vote, the Company has determined that the Company will conduct
the advisory vote annually.
Amended and Restated Novelion 2017 Equity Incentive
Plan.
The Companys shareholders approved the Amended and Restated
Novelion 2017 Equity Incentive Plan, as disclosed in the
Companys Proxy Statement. The voting results for this proposal
were as follows:
|
For |
|
Against |
|
Abstaining |
|
BrokerNon-Votes |
|
7,835,866 |
2,567,680 |
|
2,557,771 |
2017 Employee Stock Purchase Plan.
The Companys shareholders approved the 2017 Employee Stock
Purchase Plan, as disclosed in the Companys Proxy Statement.
The voting results for this proposal were as follows:
|
For |
|
Against |
|
Abstaining |
|
BrokerNon-Votes |
|
10,299,706 |
103,840 |
|
2,557,771 |
About Novelion Therapeutics Inc. (NASDAQ:NVLN)
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
